Emcure's Poviztra Gets CDSCO Approval for Fatty Liver Treatment

Emcure Gets CDSCO Approval for Using Povizta for Liver Disease Treatment

Get latest articles and stories on Business at LatestLY. The company said the approval allows Poviztra, its co-marketed brand of innovator semaglutide (rDNA origin), to be used for treating non-cirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3). Business News | Emcure Gets CDSCO Approval for Using Povizta for Liver Disease Treatment.

Emcure's Poviztra gets CDSCO approval for fatty liver treatment

Emcure's semaglutide brand Poviztra has received CDSCO approval for treating MASH, expanding access to fatty liver treatment in India.

Emcure to expand use of Poviztra for MASH indication after CDSCO nod

Emcure Pharmaceuticals announced that Poviztra®, its co-marketed brand of innovator semaglutide (rDNA origin), will now be available for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3), following the Central Drugs Standard Control Organization’s (CDSCO) approval of Wegovy® for the indication. A company statement informed, “The approval makes the in…